CA3070178A1 - Probenecid for use in treating epileptic diseases, disorders or conditions - Google Patents

Probenecid for use in treating epileptic diseases, disorders or conditions Download PDF

Info

Publication number
CA3070178A1
CA3070178A1 CA3070178A CA3070178A CA3070178A1 CA 3070178 A1 CA3070178 A1 CA 3070178A1 CA 3070178 A CA3070178 A CA 3070178A CA 3070178 A CA3070178 A CA 3070178A CA 3070178 A1 CA3070178 A1 CA 3070178A1
Authority
CA
Canada
Prior art keywords
probenecid
subject
salt
acid
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070178A
Other languages
English (en)
French (fr)
Inventor
Nathalie ROUACH
Elena Dossi
Gilles HUBERFELD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Paris Sciences et Lettres
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Universite Paris Cite
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Paris Sciences et Lettres
Universite de Paris
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Universite Paris Sciences et Lettres, Universite de Paris, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA3070178A1 publication Critical patent/CA3070178A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3070178A 2017-07-13 2018-07-13 Probenecid for use in treating epileptic diseases, disorders or conditions Pending CA3070178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305934.6 2017-07-13
EP17305934.6A EP3427729A1 (en) 2017-07-13 2017-07-13 Probenecid for use in treating epileptic diseases, disorders or conditions
PCT/EP2018/069092 WO2019012109A1 (en) 2017-07-13 2018-07-13 PROBENECID FOR USE IN THE TREATMENT OF EPILEPTIC DISEASES, DISORDERS OR DISORDERS

Publications (1)

Publication Number Publication Date
CA3070178A1 true CA3070178A1 (en) 2019-01-17

Family

ID=59384111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070178A Pending CA3070178A1 (en) 2017-07-13 2018-07-13 Probenecid for use in treating epileptic diseases, disorders or conditions

Country Status (6)

Country Link
US (2) US12318358B2 (enExample)
EP (2) EP3427729A1 (enExample)
JP (1) JP7369693B2 (enExample)
CN (2) CN111386107A (enExample)
CA (1) CA3070178A1 (enExample)
WO (1) WO2019012109A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128034B2 (en) 2020-03-11 2024-10-29 Iterum Therapeutics International Limited Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法
EP4505999A1 (en) 2023-08-07 2025-02-12 Panntherapi Probenecid formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US902695A (en) 1907-12-31 1908-11-03 Stasia B Staley Package-tie.
JPS586027A (ja) 1981-07-01 1983-01-13 住友電気工業株式会社 高圧ケ−ブルの接続部
GB2104078B (en) 1981-08-14 1985-01-23 London Polytech New aminoacid isomers, their production and their medicinal use
HUT40447A (en) 1984-03-29 1986-12-28 Sandoz Ag Process for preparing substituted alpha-amino acids and pharmaceutical compositions containing such compounds
CA1248531A (en) 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
US4906621A (en) 1985-05-24 1990-03-06 Ciba-Geigy Corporation Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade
US4746653A (en) 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4657899A (en) 1986-04-09 1987-04-14 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors
IE66149B1 (en) 1986-09-16 1995-12-13 Novo Nordisk As Quinoxaline compounds and their preparation and use
US4812458A (en) 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
US4705781A (en) 1986-10-08 1987-11-10 Giba-Geigy Corporation Method of treating cerebral ischemia using 4-(phosphono substituted lower alkyl or lower alkenyl)piperazine-2-carboxylic acids and salts, esters and amides thereof
GB8625941D0 (en) 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
IL84492A0 (en) 1986-11-21 1988-04-29 Ciba Geigy Ag Unsaturated phosphonic acids and derivatives
GB8703749D0 (en) 1987-02-18 1987-03-25 Sandoz Ltd Piperazinecarboxylic acid
US4761405A (en) 1987-03-04 1988-08-02 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
DK146787A (da) 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
PH27591A (en) 1987-08-04 1993-08-31 Ciba Geigy Ag A process for the manufacture of novel unsaturated amino acid compound
GB8719102D0 (en) 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
US4918064A (en) 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury
NO179551C (no) 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
GB8727792D0 (en) 1987-11-27 1987-12-31 Merck Sharp & Dohme Therapeutic agents
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US4968678A (en) 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
JPH0210544A (ja) 1988-06-29 1990-01-16 Canon Inc 光磁気記憶装置
EP0342558B1 (en) 1988-05-16 1994-02-02 G.D. Searle & Co. 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders
DK160941C (da) 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
GB8823605D0 (en) 1988-10-07 1988-11-16 Merck Sharp & Dohme Therapeutic agents
CA2000901A1 (en) 1988-10-21 1990-04-21 Alexis A. Cordi Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury
DK715888D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DK716188D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
US5187171A (en) 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
DE69029668T2 (de) 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US4902687A (en) 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
ATE112282T1 (de) 1989-04-07 1994-10-15 Ciba Geigy Ag Ungesättigte aminodicarbonsäurederivate.
GB8908529D0 (en) 1989-04-14 1989-06-01 Merck Sharp & Dohme Therapeutic agents
US4960786A (en) 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
CA2025326C (en) 1989-09-19 2001-04-24 Jeffrey P. Whitten Nmda antagonists
EP0420806B1 (de) 1989-09-26 1995-07-05 Ciba-Geigy Ag Phosphonsäure, Verfahren zur Herstellung und Verwendung als Arzneimittelwirkstoff
DK0501378T3 (da) * 1991-02-28 1995-03-20 Merrell Dow Pharma NMDA-antagonister
ATE162075T1 (de) 1991-09-09 1998-01-15 Warner Lambert Co Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists

Also Published As

Publication number Publication date
JP7369693B2 (ja) 2023-10-26
RU2020106762A3 (enExample) 2021-11-10
CN120478323A (zh) 2025-08-15
CN111386107A (zh) 2020-07-07
EP3651758A1 (en) 2020-05-20
JP2020527172A (ja) 2020-09-03
US12318358B2 (en) 2025-06-03
EP3427729A1 (en) 2019-01-16
US20250288544A1 (en) 2025-09-18
RU2020106762A (ru) 2021-08-13
WO2019012109A1 (en) 2019-01-17
US20200163916A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
US20250288544A1 (en) Probenecid for use in treating epileptic diseases, disorders or conditions
DK2035029T3 (en) PEPTID RELATIONS FOR TREATMENT OF REFRACTOR STATUS EPILEPTICUS.
US11221329B2 (en) Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
US20250049790A1 (en) Treatment of neurological disorders
AU2017383127B2 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
US20210128537A1 (en) T-type calcium channel modulators and methods of use thereof
RU2785842C2 (ru) Применение пробенецида для лечения эпилептических заболеваний, нарушений и состояний
KR20070085973A (ko) 수면 장애 예방 또는 치료제
EP3096790B1 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP4301351A1 (en) Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
Reeb et al. Glutamate transporters in health and disease
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
JP5714572B2 (ja) 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法
Reeb et al. Glutamate Transporters in Health
JP2021505668A (ja) 併用療法（睡眠障害およびｃｎｓ障害）において使用するためのｎｍｄａ受容体モジュレーター（ラパスチネル）の組合せ
RU2786476C2 (ru) Композиция, содержащая антитело против протофибрилл абета и ингибитор бета-секретазы васе1 для лечения болезни альцгеймера
WO2025189166A1 (en) Pharmaceutical compounds for treatment of bipolar disorder
CN119384295A (zh) 以纹状体纹状小体的多巴胺d1信号为靶点的强迫性障碍的药物疗法
JPWO2000007593A1 (ja) 難治性てんかんの治療薬又は予防薬

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230510

EEER Examination request

Effective date: 20230510

EEER Examination request

Effective date: 20230510